Chapters - Europe - Committees - Industry Committee
Industry Committee Members
- Yves Bayon (Chair)
- Michael Raghunath (Co-Chair)
- Alain Vertes
- Vincent Ronfard
- SYIS Representatives: Erik Samuelsson
2012 TERMIS World Congress
TERMIS-AM and TERMIS-EU Industry Committee Symposium
Friday, September 7, 2012 in Vienna, Austria
Introduction for Session 1 . Dr. Yves Bayon
Prof. Dr. Hartmut Ehrlich (Baxter, Head RD Baxter Bioscience; Vienna, Austria)
Alain Vertes (London Business School , Sloan Fellow; London, UK)
"Commercialization of Regenerative Products: The Academia/Industry Partnership"
Arshad Ahmed (Scientia Advisors, Partner & co-founder; Boston, USA)
"Commercializing regenerative medicine therapeutics and sustaining a successful business"
Art J Coury (Consultant; former Vice President R&D Biomaterials, Genzyme; Boston, USA)
"Translating academic concepts to commercial medical products - A complex Academic/industrial partnership"
Charlie R Campion (Apatech / Baxter, London, UK)
"ApaTech as an example of how .academia / industry partnerships. can overcome barriers to commercialization of regenerative medicine products.
Lucia D.Apote(European Medicines Agency [EMEA], Committee for Advanced Therapies [CAT], Scientific Administrator; London, UK)
Lecture on the European regulatory environment of regenerative medicine
Celia Witten(FDA.s Center for Biologics Evaluation and Research [CBER], Director of the Office of Cellular, Tissue and Gene Therapy, Washington, USA)
Lecture on the US regulatory environment of regenerative medicine
Roundtable with the US and European regulatory officers and
Alison Wilson(CellData Services, Principal Consultant; York, UK)
Tim Bertram(Tengion, Executive Vice President Science & Technology, Chief Scientific Officer; Winston-Salem, USA)
Maria-Pascual Martinez(TiGenix, Vice President of Regulatory Affairs; Spain & Belgium)
Robert Mays(Athersys, Senior Director of Regenerative Medicine; Cleveland, USA)